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Clindamycin may be active against methicillin-resistant Staphylococcus aureus, a common pathogen causing sepsis in infants,
but optimal dosing in this population is unknown.We performed amulticenter, prospective pharmacokinetic (PK) and safety
study of clindamycin in infants. We analyzed the data using a population PK analysis approach and included samples from two
additional pediatric trials. Intravenous data were collected from 62 infants (135 plasma PK samples) with postnatal ages of<121
days (median [range] gestational age of 28 weeks [23 to 42] and postnatal age of 17 days [1 to 115]). In addition to body weight,
postmenstrual age (PMA) and plasma protein concentrations (albumin and alpha-1 acid glycoprotein) were found to be signifi-
cantly associated with clearance and volume of distribution, respectively. Clearance reached 50% of the adult value at PMA of
39.5 weeks. Simulated PMA-based intravenous dosing regimens administered every 8 h (<32 weeks PMA, 5 mg/kg; 32 to 40
weeks PMA, 7 mg/kg;>40 to 60 weeks PMA, 9 mg/kg) resulted in an unbound, steady-state concentration at half the dosing in-
terval greater than a MIC for S. aureus of 0.12g/ml in>90% of infants. There were no adverse events related to clindamycin
use. (This study has been registered at ClinicalTrials.gov under registration no. NCT01728363.)
Gram-positive organisms account for 70% of late-onset sepsisin the neonatal intensive care unit (NICU), most commonly
coagulase-negative staphylococci and Staphylococcus aureus (1).
In the NICU, S. aureus infections are associated with severe pneu-
monia, septic shock, and high mortality in infants (25%) (2, 3).
In addition, a large fraction of S. aureus isolates in this setting are
methicillin resistant (3).
Clindamycin is a lincosamide antibiotic approved by the U.S.
Food and Drug Administration (FDA) for use in adults and chil-
dren requiring treatment for staphylococcal, streptococcal, and
anaerobic infections. Doses of 15 to 20 mg/kg/day are recom-
mended for infants 1 month of age, and doses of 20 to 40 mg/
kg/day are recommended for children 1 month to 16 years old
(both administered in three or four divided doses) (4). The avail-
able data suggest that there are important age-dependent differ-
ences in clindamycin disposition, particularly in preterm infants,
where pronounced physiological differences are expected (5, 6).
Clindamycin is largely metabolized by CYP3A4 (7), and the on-
togeny of this drug-metabolizing enzyme may contribute to pro-
nounced differences in its clearance (CL). Furthermore, clinda-
mycin is highly protein bound (78 to 94%) (8–10), primarily to
alpha-1 acid glycoprotein (AAG), and ontogenic changes in this
plasma protein during childhood and infancy may also alter clin-
damycin’s distribution into tissues.
Despite the public health need for rigorous clinical trials to be
performed in children during the first few months after birth, drug
labeling changes frequently do not include neonatal data (11).
Preterm infants, who are a particularly vulnerable subpopulation
due to immaturity in their organ systems, are rarely studied, and
thus optimal dosing and safety information is lacking. Due to
clindamycin’s widespread use in infants (12), we performed a pro-
spective, multicenter clinical trial to characterize its developmen-
tal pharmacokinetics (PK) and safety in preterm and term infants.
Relative to our previous investigation (13), this trial provided
more intense PK sampling in preterm and term infants, sought to
account for the role of age-dependent AAG concentrations on
clindamycin disposition, and collected detailed safety data in in-
fants, which are currently lacking in the literature.
MATERIALS AND METHODS
Patient population. PK and safety data were collected as part of the Phar-
macokinetics of Anti-Staphylococcal Antibiotics in Infants clinical trial
(Staph Trio; NICHD-2012-STA01, ClinicalTrials.gov NCT01728363;
IND 115,396). This was a multicenter (n  8 enrolling under clindamy-
cin), prospective, multiple-dose PK and safety study. Infants with a sus-
pected systemic infection or receiving one of three antibiotic drugs of
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interest per local standard of care (including clindamycin) were eligible
for enrollment. For the clindamycin group, infants were30 weeks’ ges-
tational age (GA) and 121 days’ postnatal age (PNA). Infants who met
any of the following criteria were excluded: allergic reactions to a study
drug, urine output  0.5 ml/kg/h, or serum creatinine 1.7 mg/dl. The
study was reviewed and approved by the local institutional review board.
Informed consent was obtained from the legal guardian of each study
participant. The first and last infants were enrolled on 8 February 2013
and 28 February 2014, respectively.
We combined clindamycin data from Staph Trio with PK data col-
lected after intravenous clindamycin administration in two additional
clinical trials: (i) Pharmacokinetics of Understudied Drugs Administered
to Children per Standard of Care (PTN POPS) and (2) Safety and Phar-
macokinetics of Multiple-Dose Intravenous and Oral Clindamycin Pedi-
atric Subjects With BMI 85th Percentile (CLIN01). Combining the data
across all three trials allowed for development of a population PK model
that describes clindamycin disposition after intravenous administration
across pediatric age groups. The PTN POPS and CLIN01 studies are de-
scribed in separate publications (13; M. Smith, D. Gonzalez, J. Goldman,
R. Yogev, J. E. Sullivan, M. Reed, R. Anand, K. Martz, K. Berezny, P. B.
Smith, M. Cohen-Wolkowiez, and K. Watt, presented at the Pediatric
Academic Societies 2015 Annual Meeting, San Diego, CA, 25 to 28 April
2015). Briefly, PTN POPS (NICHD-2011-POP01, ClinicalTrials.gov
NCT01431326; IND 113,645) was a multicenter (n 27), prospective, PK
and safety study. PTN POPS enrolled children (21 years of age) who
received a drug of interest (including clindamycin) per standard of care as
administered by their treating caregiver. CLIN01 (NICHD-2012-CLN01,
ClinicalTrials.gov NCT01744730; IND 115,396) was a prospective, mul-
ticenter (n 6), open-label, multiple-dose PK and safety study of clinda-
mycin in children 2 to18 years of age with a body mass index (BMI)
85th percentile. Children with a suspected or confirmed infection or those
receiving clindamycin per standard of care were eligible for the study.
Drug dosing and sample collection. In the Staph Trio trial, all infants
received clindamycin 10 mg/kg intravenously every 6, 8, or 12 h unless
they were prescribed clindamycin per standard of care, in which case
dosing was at the discretion of the treating caregiver. The dosing interval
used was based on PNA:14 days, 10 mg/kg every 12 h;14 to 45 days,
10 mg/kg every 8 h; and45 to 120 days, 10 mg/kg every 6 h. Clindamycin
was administered over 30 min. Predefined PK sample time collection win-
dows based on dosing interval were noted in the protocol (see Table S1 in
the supplemental material); however, samples collected outside these col-
lection windows were also included in the analysis.
For the PTN POPS study, dosing information was collected for up to
eight doses prior to the sampling dose (last dose before biological sample
collection). Since PTN POPS used an opportunistic study design, the
timing of blood sample collection was dependent on standard-of-care
laboratory assessments, unless a parent/guardian provided consent to ob-
tain PK sampling for research purposes only (13). In the CLIN01 trial,
clindamycin was prescribed at a dose of 30 to 40 mg/kg/day (based on the
total body weight [WT]) every 6 or 8 h. Predefined PK sampling times
used were based on route of administration and dosing interval (Smith et
al., Pediatric Academic Societies 2015 Annual Meeting).
Analytical methods. Whole blood was collected (200 l) in an
EDTA-K2 microtainer and processed immediately prior to freezing at the
study sites. Plasma samples were stored at or below 70°C within 8 h of
collection. PK samples were sent to the Pediatric Trials Network central
laboratory (OpAns, LLC, Durham, NC) for storage and analysis. Clinda-
mycin concentrations were quantified using a validated liquid chroma-
tography-tandem mass spectrometry assay as previously described (13).
The lower limit of quantification was 50 ng/ml. Accuracy and precision
were within the FDA bioanalytical assay validation criteria (e.g.,15%).
An enzyme-linked immunosorbent assay (Assaypro LLC, St. Charles,
MO) was used for the measurement of AAG in plasma. The method was
qualified over the range 0.125 to 4g/ml for human AAG in MIX Diluent
(a buffered protein base supplied with the kit) representing 0.125 to 4
mg/ml corrected for dilution. Both calibration standards and quality con-
trol samples met assay validation criteria. Each study sample was diluted
1:1,000 into MIX Diluent and then processed in duplicate.
Population PK model development. Clindamycin plasma PK data
collected after intravenous administration were analyzed with a nonlinear
mixed effects modeling approach using the software NONMEM (version
7.2; Icon Solutions, Ellicott City, MD). The first-order conditional
estimation method with interaction was used for all model runs. Run
management was performed using Pirana (version 2.8.1) (14). Visual pre-
dictive checks and bootstrap methods were performed with Perl-speaks-
NONMEM (PsN, version 3.6.2) (15). Data manipulation and visualiza-
tion were performed using R (version 3.0.2; R Foundation for Statistical
Computing, Vienna, Austria) and RStudio (version 0.97.551; RStudio,
Boston, MA), with the packages lattice and ggplot2 used for the latter
(16, 17).
As previously described, a one-compartment structural PK model was
used (13). Interindividual variability was assessed for PK model parame-
ters using an exponential relationship. The correlation between 	 param-
eters for CL and volume of distribution (V) was estimated according to
equation 1:
 
CL,V
CL2 ·V2
(1)
where 
CL,V denotes the off-diagonal element between CL and V, and

CL
2 and
V
2 are the variance estimates for the interindividual variability
in CL and V, respectively. A proportional error model was used to esti-
mate the residual variability for each study (Staph Trio, PTN POPS, and
CLIN01) separately.
WT was assumed to be a significant covariate for CL and V and was
included in the base model. The relationship between WT and PK param-
eters was characterized using a fixed exponent (0.75 and 1) allometric and
linear relationship for CL and V parameters (scaled to a 70-kg standard-
ized WT), respectively. Because postmenstrual age (PMA) was previously
noted to be an important predictor of interindividual variability in clin-
damycin disposition in the pediatric population, this covariate was again
tested. The following covariates were then also explored: aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), serum creatinine,
bilirubin (total and direct), serum albumin (ALB), AAG, obese status
(BMI 95th percentile), ethnicity, and sex. PMA is defined as the sum of
the GA (weeks) plus PNA in weeks (days/7).
The relationship between PMA and CL was characterized using a sig-
moidal EMAX maturation function as shown in equation 2:
FPMA 
PMAHILL
TM50
HILL  PMAHILL
(2)
where FPMA denotes the fraction of the adult CL value, TM50 represents
the value of PMA (weeks) when 50% adult CL is reached, and “HILL” is a
slope parameter for the sigmoidal maturation model.
With the exception of WT and age, all other continuous covariates
were normalized to the population median value as described in equation
3, whereas for dichotomous categorical covariates (e.g., obese status and
sex) a relationship, as shown in equation 4, was used:
Pij pop,j ·  covicovm 
cov
(3)
Pij pop,j·cov CATEGORICAL (4)
where covi denotes the individual covariate value, covm is the population
median covariate value, cov is a parameter which represents the covariate
effect, and “CATEGORICAL” is a categorical variable that can take on one
of two values: zero or one.
A forward inclusion (P  0.05 and change in objective function
value  3.8) and backward elimination (P  0.001 and change in
objective function value  10.8) approach was used to assess the sta-
tistical significance of relevant covariates. Missing covariate values
were imputed using the median value for the sample.
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Population PKmodel evaluation. During the population PK model-
building process, the following tools or criteria were used to assess model
robustness: successful minimization, standard diagnostic plots, plausibil-
ity and precision of parameter estimates, objective function and shrinkage
values, and visual predictive checks. Parameter precision for the final pop-
ulation PK model was evaluated using nonparametric bootstrapping
(1,000 replicates) to generate 95% confidence intervals for parameter es-
timates using the percentile method.
Dosing simulations. The final population PK model was used to sim-
ulate steady-state exposure in preterm and term infants following previ-
ously recommended (13) intravenous dosing regimens:32 weeks PMA,
5 mg/kg every 8 h;32 to 40 weeks PMA, 7 mg/kg every 8 h; and40 to
60 weeks PMA, 9 mg/kg every 8 h. The steady-state area under the con-
centration versus time curve from 0 to 8 h (AUCss,0 – 8), maximal steady-
state concentration (Css,max), and steady-state concentration at half the
dosing interval (Css,50) were calculated according to equations 5 to 7:
AUCss,0–8 
Dose
CL
(5)
Css,max 
Dose
CL · DUR ·
1	 EXP	Ke · DUR
1	 EXP	Ke · 
 (6)
Css,50  Css,max · EXP	Ke · 3.5 (7)
where Ke denotes the first-order elimination rate constant calculated as
CL/V, “DUR” denotes the infusion duration (0.5 h for all dosing simula-
tions), and  is the dosing interval (8 h for all dosing simulations). Cova-
riate values used in the simulations were the same as those in the study
population used for model development. A total of 200 concentrations
versus time profiles were simulated for each virtual patient. A maximum
absolute dose of 900 mg every 8 h and infusion duration of 0.5 h were used
in all dosing simulations.
Finally, the simulated unbound, steady-state concentration at half the
dosing interval (fCss,50) was calculated for each virtual subject assuming a
fraction unbound of 17% (9). The proportion of virtual participants with
an fCss,50 greater than an MIC of 0.12 g/ml (previously reported MIC90
for S. aureus) after the optimal dosing was calculated (18).
Safety. Safety was assessed from the time of informed consent through
72 h and 7 days after the last dose for adverse events and serious adverse
events, respectively. For standard of care clindamycin dosing, the last dose
was defined as the sixth dose after enrollment. The safety data were re-
viewed on a quarterly basis by the Best Pharmaceuticals for Children Act
data monitoring committee convened by the National Institute of Child
Health and Human Development. An adverse event was defined as any
untoward medical occurrence that took place during the conduct of the
study trial regardless of whether it was drug related. A serious adverse
event was an event that resulted in any of the following outcomes: death,
life-threatening adverse event, persistent or significant incapacity or dis-
ruption in the ability to perform normal life functions, inpatient hospi-
talization or prolonging an existing hospitalization, or an important med-
ical event that jeopardized the health of a study participant.
RESULTS
Patient characteristics. We enrolled 21 infants with a median
(range) GA and PNA of 26 weeks (23 to 29) and 23 days (5 to 65),
respectively. We collected 75 PK samples, of which eight scav-
enged (leftover samples from routine patient care) samples, two
samples below the limit of quantification, and one sample with
uncertain timing were not included in the analysis. The median
(range) number of samples per infant was three (2 to 4). The
median (range) clindamycin doses were 9.8 mg/kg/dose (4.3 to
13.0) and 28.9 mg/kg/day (10.0 to 39.5).
We combined the data from this prospective clinical trial with
additional PK samples collected from preterm and term infants in
PTN POPS, a separate opportunistic study (Table 1) (13). From
this study, there were 41 infants with a121-day PNA who con-
tributed 71 PK samples (median [range] per subject of 2 [1 to 5]).
The median (range) GA and PNA values were 33 weeks (22 to 42)
and 16 days (1 to 115), respectively. The median (range) clinda-
mycin dose was 5.1 mg/kg/dose (3.8 to 13.5) and 15.0 mg/kg/day
(7.6 to 40.6).
Population PKmodel development and evaluation. The data
across three trials (total n  220 subjects; 420 PK samples) were
pooled to develop a population PK model that characterizes clin-
damycin disposition across all pediatric age groups (see Table S2
in the supplemental material). CLIN01 included 89 plasma PK
samples from 21 overweight or obese children. After accounting
TABLE 1 Clinical data for preterm and term infants121 days of agea
Characteristic
GA 30 wk GA 30 wk
PNA 14 days
(n 16)
PNA 14–45
days (n 16)
PNA 45–120
days (n 6)
PNA 14 days
(n 9)
PNA 14–45
days (n 5)
PNA 45–120
days (n 10)
GA (wk) 26.0 (22.9–29.7) 26.5 (23.0–28.9) 27.5 (24.0–29.0) 36.6 (31.1–40.0) 39.0 (37.0–39.7) 38.1 (30.0–42.0)
PNA (days) 4.9 (2.1–10.0) 22.5 (14.0–44.0) 58.9 (51.0–64.0) 6.3 (0.8–13.0) 16.1 (16.0–29.9) 78.5 (53.0–115.2)
Postmenstrual age (wk) 27.0 (23.6–30.0) 29.1 (25.7–34.3) 36.2 (31.3–37.1) 36.7 (32.0–41.4) 41.6 (39.3–42.0) 49.2 (37.6–56.3)
Wt (kg) 0.8 (0.5–1.2) 1.0 (0.6–2.6) 1.8 (1.4–3.0) 2.5 (1.2–3.8) 3.7 (2.4–4.4) 5.8 (1.9–8.8)
Serum creatinine (mg/dl) 1.0 (0.5–1.5) 0.5 (0.2–1.5) 0.3 (0.2–0.8) 0.4 (0.3–0.8) 0.3b 0.2 (0.2–0.3)
AST (U/liter) 21.0 (15.0–34.0) 24.5 (16.0–87.0) 109.0 (30.0–116.0) NS 24.5 (21.0–28.0) 29*
ALT (U/liter) 6.0 (6.0–11.0) 15.5 (6.0–47.0) 41.0 (20.0–55.0) NS 33.0 (11.0–55.0) 25*
Total bilirubin (mg/dl) 5.3 (2.3–7.7) 2.8 (0.5–8.2) 4.9 (3.5–7.9) 8.5* 1.4 (0.5–2.2) 0.5*
Albumin (g/dl) 2.3 (1.9–2.8) 2.3 (1.3–2.7) 2.2 (2.1–2.3) NS 3.0 (2.1–3.7) 3.3 (2.6–4.0)
AAG (mg/ml) 1.2 (0.4–3.8) 1.0 (0.2–2.9) 1.3 (0.7–2.1) 2.2 (0.9–3.3) 2.1 (1.3–2.5) 2.1 (1.3–6.3)
No. of subjects (%)
Male 10 (63) 6 (38) 5 (83) 5 (56) 2 (40) 9 (90)
Caucasian 13 (81) 15 (94) 3 (50) 6 (67) 5 (100) 10 (100)
Hispanic 4 (25) 2 (13) 1 (17) 1 (11) 2 (40) 3 (30)
a Values are medians (ranges) for continuous variables and no. (%) for categorical variables calculated based on values at the time of the first recorded dose. For categorical
variables, the percentages were calculated as a function of the number of subjects in each study. GA, gestational age; PNA, postnatal age; Wt, total body weight; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; AAG, alpha-1 acid glycoprotein; NS, no subjects contributed data; *, one subject contributed data.
b Three subjects contributed data, but each had the same value.
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for body size using WT, inclusion of PMA on CL and ALB and
AAG on V further reduced the objective function value by 115.6,
18.5, and 9.2 points, respectively. Inclusion of serum creatinine on
CL also significantly reduced the objective function value (11.6
points) but was not included in the final model because its reten-
tion in the model was largely a result of one influential individual
(with a value of 3.4 mg/dl). No other covariates reached statistical
significance.
For the final model, the typical values for CL and V can be
expressed according to the following equations: CL (liters/h) 
13.8 · (WT/70)0.75 · [PMA2.83/(39.52.83  PMA2.83)]; V (liters) 
63.6 · (WT/70) · (ALB/3.3)0.83 · (AAG/2.4)0.25 (see Table S3 in
the supplemental material). There was an inverse relationship be-
tween AAG levels and weight-normalizedV (Fig. 1). Eta shrinkage
estimates for CL and V were 6.2 and 23.6%, respectively; epsilon
shrinkage estimates for PTN POPS, Staph Trio, and CLIN01 were
25.8, 13.7, and 11.9%, respectively. Goodness-of-fit plots and a
visual predictive check for all data included in the analysis are
shown in Fig. S1 to S3 in the supplemental material. Empirical
Bayesian estimates stratified by age are shown in Table 2. Clear-
ance values increased with age, whereas V decreased with age due
in part to increasing plasma protein concentrations.
Dosing simulations.PMA-based dosing (32 weeks, 5 mg/kg;
32 to 40 weeks, 7 mg/kg; 40 to 60 weeks, 9 mg/kg; each regi-
men administered intravenously every 8 h) resulted in compara-
ble AUCss,0 – 8 (median [2.5th to 97.5th quantiles] 33.8 g · h/ml
[10.5 to 110]) andCss,max (median [range] 7.9g/ml [3.4 to 18.3])
across all infant age categories (Fig. 2) (19). The fCss,50 was greater
than the MIC for S. aureus of 0.12 g/ml in 97% of virtual
infants.
For infants5 months to 1 year PNA, 12 mg/kg administered
intravenously every 8 h resulted in a median (2.5th to 97.5th quan-
tiles) simulated AUCss,0 – 8 and Css,max of 41.2 g · h/ml (13.0 to
137.0) and 14.1 g/ml (9.2 to 26.7), respectively. The fCss,50 was
0.12 g/ml for 94.3% of the virtual infants.
Safety. Nine (43%) infants experienced a total of 14 adverse
events, none of which were deemed related to study drug. The 14
adverse events were as follows (n [%]): seizures (3 [21%]), anemia
(2 [14%]), worsening necrotizing enterocolitis (NEC) (1 [7%]),
worsening spontaneous bowel perforation (1 [7%]), respiratory
acidosis (1 [7%]), hypotension (1 [7%]), abdominal wound de-
hiscence from NEC surgery (1 [7%]), diaper rash (1 [7%]),
chronic lung disease (1 [7%]), neonatal feeding intolerance (1
[7%]), and grade I intraventricular hemorrhage (1 [7%]).
The three infants who experienced a seizure were 25 to 26
weeks’ GA and21 days’ PNA and received a median clindamy-
cin dose of 10 mg/kg intravenously every 12 h. Based on their
empirical Bayesian estimates and dosing, their predicted steady-
state area under the concentration versus time curves from zero to
12 h (AUCss,0 –12) were 17.9, 93.9, and 108.6 g · h/ml; the Css,max
FIG 1 (A) Alpha-1 acid glycoprotein versus volume of distribution (V); (B) postmenstrual age versus V. The black line and shaded area denote the loess curve
and an associated 95% confidence region.
TABLE 2 Individual empirical Bayesian post hoc parameter estimates stratified by age
Parameter
Median (range)a
PMA 28 wk
(n 16)
PMA 28–32 wk
(n 14)
PMA 32–40 wk
(n 16)
PMA 40–60 wk
(n 18)
PNA 5 mo to 1
year (n 15)
CL (liters/h) 0.11 (0.05–0.55) 0.23 (0.06–0.36) 0.50 (0.06–2.89) 1.37 (0.17–6.35) 1.90 (0.63–5.75)
CL (liters/h/kg) 0.14 (0.07–0.55) 0.19 (0.06–0.42) 0.24 (0.06–1.13) 0.28 (0.08–0.93) 0.28 (0.14–0.61)
CL (liters/h/70 kg) 3.31 (1.55–13.2) 4.91 (1.44–9.21) 7.37 (1.33–34.5) 10.0 (2.24–36.49) 10.97 (4.95–25.72)
V (liters) 1.15 (0.49–2.31) 1.00 (0.67–2.46) 2.72 (0.70–5.43) 4.56 (1.53–9.86) 6.12 (3.17–11.10)
V (liters/kg) 1.20 (0.87–2.26) 1.30 (0.74–1.88) 1.03 (0.70–2.12) 0.99 (0.64–1.27) 0.83 (0.70–1.17)
V (liters/kg/70 kg) 83.50 (61.17–158.51) 90.95 (51.59–130.92) 71.90 (49.14–147.90) 68.99 (44.68–88.84) 57.90 (49.10–81.79)
Half-life (h) 5.89 (2.42–12.90) 5.25 (2.34–8.87) 3.96 (1.30–8.83) 2.35 (0.94–6.44) 2.05 (1.26–3.47)
a PMA, postmenstrual age; PNA, postnatal age; CL, clearance; V, volume of distribution.
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values were 5.2, 10.7, and 14.2 g/ml. In four subjects who re-
ceived clindamycin intravenous dosing every 12 h (5 to 10 mg/kg/
dose) and did not experience a seizure, the median (range)
AUCss,0 –12 and Css,max were 42.2 g · h/ml (28.8 to 57.3) and 6.7
g/ml (4.1 to 9.1), respectively.
DISCUSSION
As previously described (13), we used a one-compartment struc-
tural PK model to find that after correcting for body size using
WT, PMA was the most significant covariate that accounts for
maturation in infants. Using a sigmoid EMAX maturation func-
tion, maturation reached 50% adult CL values at 39.5 weeks’
PMA, comparable to other CYP3A4 substrates (e.g., 39.7 weeks
with lopinavir) (20, 21). The population estimates for CL and V
were 13.8 liters/h and 63.6 liters (scaled to a 70-kg standardized
adult WT), respectively, which were comparable to reported adult
values of 15.2 liters/h and 66.2 liters, respectively (22).
In addition to body size and age (PMA), plasma protein con-
centrations (AAG and ALB) significantly explained interindi-
vidual variability in V. Clindamycin binds primarily to AAG, and
changes in the concentrations of this protein would be expected to
alter its fraction unbound in infants (8–10, 23) A reduction in V
with age was observed in part due to increased AAG concentra-
tions, which is consistent with a previous investigation that pre-
dicted 50% adult concentrations at birth (24). A trend toward
lower ALB levels in infants was also observed (40% lower in
infants28 weeks versus40 to 60 weeks PMA), but a substantial
fraction of subjects were lacking an available measurement.
We compared our individual clindamycin PK estimates with
two previous studies in infants (5, 6). One study that enrolled 40
preterm and term infants (GA, 28 to 40 weeks; PNA, 2 to 27 days;
WT, 1 to 9.6 kg) and administered intravenous clindamycin (15 to
20 mg/kg/day) noted increases in CL with PNA (0.29 liter/h for
preterm and 28 days PNA, 0.68 liter/h for term and 28 days
PNA, and 1.59 liter/h for 4 weeks of age) (5). Although not
statistically significant, the authors noted that V was three times
higher in preterm infants (relative to term infants  28 days and
infants 4 weeks of age) (5). A second study enrolled 12 newborn
infants (GA, 26 to 39 weeks; PNA, 1 to 24 days; WT, 0.8 to 2.6 kg)
and reported a mean (range) weight-normalized V and CL of 0.56
liter/kg (0.15 to 1.1) and 0.06 liter/h/kg (0.02 to 0.13), respectively
(6). These estimates of CL and V are in agreement with the values
observed in our study, whereby preterm infants had the lowest CL
and highest V estimates.
The treatment regimens simulated in our study were within the
range of recommended doses in the package insert but were fur-
ther stratified based on the PMA of the infant. The regimens we
simulated resulted in comparable simulated exposure relative to
adult estimates (19). The exposures were comparable even when
plotted as a function of weight and varying AAG and ALB concen-
FIG 2 Simulated steady-state area under the total clindamycin concentration versus time curve from 0 to 8 h (AUCss,0 – 8) after intravenous dosing to achieve
exposure comparable to observed adult values after 600 mg intravenously every 8 h (mean [standard deviation], 31.8 g · h/ml [6.7]) (19). (A and B) AUCss,0 – 8
versus postmenstrual age and total body weight after age-based dosing:32 weeks’ postmenstrual age, 5 mg/kg every 8 h;32 to 40 weeks’ postmenstrual age,
7 mg/kg every 8 h; and40 to 60 weeks’ postmenstrual age, 9 mg/kg every 8 h. (C and D) AUCss,0 – 8 versus postnatal age and total body weight after 12 mg/kg
every 8 h for infants 5 months to 1 year of age. The shaded regions denote the 90% (95th and 5th percentiles), 80% (90th and 10th percentiles), and 50% (75th
and 25th percentiles) prediction intervals from lightest to darkest color intensity, respectively. The dashed black lines denote the 95th, 75th, 25th, and 5th
percentiles, respectively. The solid black line is the median.
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trations. Furthermore, a high percentage of infants (94%) up to
1 year of age had simulated concentrations above an MIC of 0.12
g/ml across all dosing regimens, which suggests that these doses
will yield a therapeutic benefit.
Clindamycin was generally well tolerated in our study. None
of the adverse events reported were deemed related to study
drug. The most common adverse events (seizures, anemia, and
worsening NEC) may be due to the inherent disease processes
in this vulnerable population. Although seizures are possibly
due to high concentrations of clindamycin, the extent of cen-
tral nervous system penetration of clindamycin in children is
unknown, and in adults the cerebrospinal fluid/plasma ratio is
low, generally 1 to 3% (25). Two of the three infants who ex-
perienced seizures had a predicted exposure in the upper range
of all infants enrolled in the infant PK study. For one of the
infants, the seizure occurred3 days after the last clindamycin
dose. A follow-up study to evaluate clindamycin safety in pre-
term and term infants is needed.
Combining clindamycin data collected across multiple PK
studies allowed us to characterize the disposition of this drug as a
function of age. We used a flexible study design, which collected
PK and safety data for three antistaphylococcal antibiotics (in-
cluding clindamycin) and then merged these data with two other
data sets. The final population PK model then allowed us to iden-
tify important covariates that explain interindividual variability
and explore clindamycin dosing. A few limitations of our ap-
proach should be noted. First, we combined data across three
clinical trials with different study designs and patient populations,
which may introduce additional variability. As a result, in our
model we estimated separate residual variability parameters for
each study. Second, in the opportunistic study, a substantial pro-
portion of the subjects were missing laboratory data (e.g., ALB),
which limited our ability to evaluate the significance of some co-
variates. However, a measurement of AAG, clindamycin’s pre-
dominant binding protein, was available for 98% of subjects
across all three studies.
Conclusion In conclusion, a one-compartment population PK
model accounting for size-based differences using WT, matura-
tion in drug CL using PMA, and differences in protein binding
using AAG and ALB concentrations characterized clindamycin
disposition in preterm and term infants. In preterm infants, clin-
damycin should be dosed using WT and PMA to achieve thera-
peutic exposures.
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